Previous studies have shown an increased risk of secondary primary malignancies (SPMs) after diffuse large B‐cell lymphoma (DLBCL) treatment. Whether stage of DLBCL at diagnosis affects the subtypes of SPMs… Click to show full abstract
Previous studies have shown an increased risk of secondary primary malignancies (SPMs) after diffuse large B‐cell lymphoma (DLBCL) treatment. Whether stage of DLBCL at diagnosis affects the subtypes of SPMs that occur has not been previously described.
               
Click one of the above tabs to view related content.